IP Verse

Shire competitive analysis

Latest publications and patents of Shire New

Explore the latest publications and patents granted to Shire, showcasing their recent innovations and technological advancements.

Last updated on: Sep 27, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Shire

EP2858679
Jun 5, 2024Pulmonary Delivery Of Mrna To Non-Lung Target CellsPatent Maintained As Amended
EP3626258
Aug 4, 2021Methods And Compositions For Cns Delivery Of Iduronate-2-SulfataseGranted And Under Opposition
EP2970456
May 19, 2021Methods And Compositions For Delivering Mrna Coded AntibodiesGranted And Under Opposition
EP3103469
Dec 9, 2020Cns Delivery Of Therapeutic AgentsGranted And Under Opposition
EP3134506
Aug 7, 2019Methods For Purification Of Messenger RnaGranted And Under Opposition
EP3071219
Nov 14, 2018Methods Of Treating Antibody-Mediated Rejection In Organ Transplant Patients With C1-Esterase InhibitorRevoked
EP3060303
Nov 14, 2018Mrna Therapy For Argininosuccinate Synthetase DeficiencyRevoked
EP3122878
Oct 24, 2018Mrna Therapy For The Treatment Of Ocular DiseasesOpposition Rejected
EP2867245
Sep 12, 2018Purification Of Iduronate-2-SulfataseRevoked
EP2506857
Feb 14, 2018Delivery Of Mrna For The Augmentation Of Proteins And Enzymes In Human Genetic DiseasesRevoked

Latest oppositions filed by Shire

Explore patent oppositions filed by Shire against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP2708559
Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules RepeatedlyCHUGAI SEIYAKU KABUSHIKI KAISHADec 21, 2018
EP2708558
Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules RepeatedlyCHUGAI SEIYAKU KABUSHIKI KAISHADec 20, 2018
EP2552955
Antibodies With Modified Affinity To Fcrn That Promote Antigen ClearanceCHUGAI SEIYAKU KABUSHIKI KAISHAFeb 5, 2018

Latest patents of Shire opposed by its competitors

Explore Shire's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2858679
Jun 5, 2024Pulmonary Delivery Of Mrna To Non-Lung Target Cells1
EP3626258
Aug 4, 2021Methods And Compositions For Cns Delivery Of Iduronate-2-Sulfatase1
EP2970456
May 19, 2021Methods And Compositions For Delivering Mrna Coded Antibodies4
EP3103469
Dec 9, 2020Cns Delivery Of Therapeutic Agents1
EP3134506
Aug 7, 2019Methods For Purification Of Messenger Rna2
EP3060303
Nov 14, 2018Mrna Therapy For Argininosuccinate Synthetase Deficiency1
EP3071219
Nov 14, 2018Methods Of Treating Antibody-Mediated Rejection In Organ Transplant Patients With C1-Esterase Inhibitor1
EP3122878
Oct 24, 2018Mrna Therapy For The Treatment Of Ocular Diseases1
EP2867245
Sep 12, 2018Purification Of Iduronate-2-Sulfatase1
EP2506857
Feb 14, 2018Delivery Of Mrna For The Augmentation Of Proteins And Enzymes In Human Genetic Diseases2

Latest PTAB cases involving Shire

Discover the latest PTAB cases involving Shire, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 3, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Shire

IPR2019-00459Dec 21, 2018CSL BEHRINGSHIRE VIROPHARMA INCORPORATEDInstitution Denied
IPR2018-00293Dec 11, 2017KVK TECHSHIREFinal Written Decision
IPR2018-00290Dec 11, 2017KVK TECHSHIREFinal Written Decision
IPR2017-01512May 31, 2017CSL BEHRINGSHIRE VIROPHARMA INCORPORATEDInstitution Denied
IPR2017-00665Jan 13, 2017AMERIGEN PHARMACEUTICALSSHIRETerminated-Settled
IPR2017-00011Oct 4, 2016MYLAN PHARMACEUTICALSSHIRE LABORATORYInstitution Denied
IPR2016-01033May 12, 2016MYLAN PHARMACEUTICALSSHIRE LABORATORIESTerminated
IPR2016-00258Nov 25, 2015GREEN CROSSSHIRE HUMAN GENETIC THERAPIESFinal Written Decision
IPR2015-02009Oct 1, 2015AMERIGEN PHARMACEUTICALSSHIREFinal Written Decision
IPR2014-00739May 9, 2014SHIRELCS GROUPTerminated-Settled

Peer Comparison New

IP litigation analysis comparing Shire with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
SHIRE HUMAN GENETIC THERAPIES314 - 1Defensive
CHUGAI SEIYAKU KABUSHIKI KAISHA376 - 1Defensive
GREEN CROSS2 - 1 - Highly Aggressive
WITHERS & ROGERS33 - - - Highly Aggressive